SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T

BACKGROUND: Quantification of [(68) Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [(18)F]-labeled radiotracers, we aimed to determine whether the uptake derived from [(18)F]PSMA-1007 PET can...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartrampf, Philipp E., Hüttmann, Thomas, Seitz, Anna Katharina, Kübler, Hubert, Serfling, Sebastian E., Schlötelburg, Wiebke, Michalski, Kerstin, Rowe, Steven P., Pomper, Martin G., Buck, Andreas K., Eberlein, Uta, Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542708/
https://www.ncbi.nlm.nih.gov/pubmed/37272956
http://dx.doi.org/10.1007/s00259-023-06281-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542708/
https://www.ncbi.nlm.nih.gov/pubmed/37272956
http://dx.doi.org/10.1007/s00259-023-06281-6

Ejemplares similares